ophthalmology therapeutics market in asia-pacific to therapeutics market in asia-pacific to 2019...

Download Ophthalmology Therapeutics Market in Asia-Pacific to Therapeutics Market in Asia-Pacific to 2019 High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity

Post on 23-Apr-2018

214 views

Category:

Documents

2 download

Embed Size (px)

TRANSCRIPT

  • Ophthalmology Therapeutics Market in Asia-Pacific to 2019 High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity

  • GBI Research Report Guidance

    GBI Research. This is a licensed product and is not to be photocopied GBIHC308MR / Published OCT 2013 Page 2

    GBI Research Report Guidance

    Chapter two provides an introduction to ophthalmology therapeutic indications of glaucoma and DES, including epidemiology, symptoms, etiology, pathophysiology, diagnosis, disease classification and determination of disease severity, and treatment.

    Chapter three is the GBI Research Report Guidance

    Chapter four provides an overview of the product profiles for seven key marketed products for glaucoma and DES.

    Chapter five analyses the glaucoma and DES pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The chapter also profiles four promising drug candidates in the pipeline.

    Chapter six provides market forecast to 2019 for APAC markets (India, Australia, China and Japan), and includes prevalence population, Annual Cost of Therapy (ACoT) and a market size forecast, along with drivers and barriers for the ophthalmology market.

    Chapter seven provides a strategic consolidation analysis, including major co-development and licensing deals.

  • GBI Research. This is a licensed product and is not to be photocopied GBIHC308MR / Published OCT 2013

    Page 3

    Ophthalmology Therapeutics Market in Asia-Pacific Executive Summary

    Ophthalmology Therapeutics Market in Asia-Pacific Executive Summary

    Ophthalmology Therapeutics Market in Asia-Pacific is Expected to Reach $XX Billion by 2019 with Modest Growth of XX%

    The ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in four Asia-Pacific (APAC) countries, India, Australia, China and Japan, was worth $XX billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of XX% to reach $XX billion by 2019.

    The Indian market is expected to show the fastest growth over the forecast period with a CAGR of XX%. The other three markets are expected to see similar but slightly lower CAGRs, with China at XX%, Australia at XX%, and Japan at XX%. In 2012, Japan had the largest market in APAC with a value of $XXm, or XX% of the total APAC ophthalmology market. The next largest market was China at $XXm or XX% of the total APAC market. In the same year, the Indian market was valued at $XXm, a share of XX%. Australia had the lowest market share at XX% with a market value of $XXm.

    Ophthalmology Therapeutics Market, APAC, Market Size ($m), 20122019

    2012 2019

    Rev

    enue

    ($m

    )

    India China Australia Japan

    CAGR (20122019): XX%India: XX%China: XX%Australia: XX% Japan: XX%

    Source: GBI Research

    Moderate Pipeline with Promising Drugs in Late Stages of Development Could Drive Market Expectations

    The global ophthalmology pipeline is becoming increasingly innovative with a cluster of novel molecules in the early stages of development. The drug approval processes in many APAC countries, including Japan and China, require clinical trials to be run domestically in order to account for differences in drug metabolism between populations of different ethnicities. This can delay new drug launches but in the long term secures greater confidence in safety and efficacy profiles. There are currently five molecules in the Pre-registration stage of development that are expected to be granted approval within the forecast period. Two of these are indicted for DES and three for glaucoma. Nearly XX% of the pipeline for glaucoma and DES are molecules in the late stages of development (Phases II and III), and of these, XX molecules (XX%) are indicated for DES and XX (XX%) for glaucoma.

    Some of the major factors driving the growth of the market are growing awareness of the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools, and an increase in the prevalence of both diseases. The expiration of blockbuster drug patents and the subsequent pressure from cheaper off-label products will be a key market restraint. A sizeable section of glaucoma patients require combination therapy the use of additional agents to the treatment regimen to control elevated intraocular pressure. The demand for combination products over single-ingredient formulations has risen, and they often improve patient compliance as the two drugs can be administered simultaneously.

    Ophthalmology Therapeutics Market in Asia-Pacific is expected to reach $XX Billion by 2019 with Modest Growth of XX%

    There are currently five molecules in the Pre-registration stage of development that are expected to be granted approval within the forecast period

  • GBI Research. This is a licensed product and is not to be photocopied GBIHC308MR / Published OCT 2013

    Page 5

    Table of Contents

    1 Table of Contents 1 Table of Contents ................................................................................................................................. 5

    1.1 List of Tables ............................................................................................................................. 8 1.2 List of Figures............................................................................................................................ 9

    2 Ophthalmology Therapeutics Market in Asia-Pacific Introduction ......................................................10 2.1 Dry Eye Syndrome....................................................................................................................10

    2.1.1 Classification ....................................................................................................................10 2.1.2 Symptoms ........................................................................................................................10 2.1.3 Etiology ...........................................................................................................................10 2.1.4 Pathophysiology...............................................................................................................11 2.1.5 Diagnosis .........................................................................................................................12 2.1.6 Epidemiology ...................................................................................................................13 2.1.7 Prognosis .........................................................................................................................14 2.1.8 Treatment Options ...........................................................................................................14

    2.2 Glaucoma ................................................................................................................................15 2.2.1 Classification ....................................................................................................................15 2.2.2 Symptoms ........................................................................................................................16 2.2.3 Etiology ...........................................................................................................................16 2.2.4 Pathophysiology...............................................................................................................17 2.2.5 Diagnosis .........................................................................................................................18 2.2.6 Epidemiology ...................................................................................................................19 2.2.7 Prognosis .........................................................................................................................19 2.2.8 Treatment Options ...........................................................................................................20

    3 Ophthalmology Therapeutics Market in Asia-Pacific Marketed Products (Global) ...............................21 3.1 Dry Eye Syndrome....................................................................................................................21 3.2 Glaucoma ................................................................................................................................21 3.3 Key Marketed Products ............................................................................................................22

    3.3.1 Restasis ...........................................................................................................................22 3.3.2 Systane ............................................................................................................................23 3.3.3 Diquas .............................................................................................................................24 3.3.4 Mucosta ..........................................................................................................................25 3.3.5 Hyalein ............................................................................................................................26 3.3.6 Lumigan...........................................................................................................................27 3.3.7 Alphagan/Alphagan P ......................................................................................................28

    4 Ophthalmology Therapeutics Market in Asia-Pacific Pipeline Analysis ................................................29 4.1 Dry Eye Syndrome Pipeline..................................................................................

Recommended

View more >